1
/
of
0
Nicmel (Nilotinib)
Nicmel (Nilotinib)
Regular price
₱8,400.00 PHP
Regular price
Sale price
₱8,400.00 PHP
Taxes included.
Quantity
Couldn't load pickup availability
Nicmel Nilotinib 150mg and 200mg Capsules — Tyrosine Kinase Inhibitor for Chronic Myeloid Leukemia and Gastrointestinal Stromal Tumors
Nicmel is a targeted tyrosine kinase inhibitor containing nilotinib as its active pharmaceutical ingredient, prescribed primarily for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). This medication works by blocking specific proteins that promote abnormal cell growth, helping to slow or stop the progression of these blood and solid tumors.
Nilotinib has demonstrated clinical efficacy in managing both newly diagnosed and treatment-resistant CML cases, with established safety and tolerability profiles across multiple patient populations. Available in 150mg and 200mg capsule strengths, Nicmel allows for flexible dosing regimens tailored to individual patient needs and clinical response.
The medication is typically administered orally on an empty stomach, as food can significantly reduce its absorption. Standard dosing protocols vary based on disease stage and patient factors, with treatment duration determined by your healthcare provider based on response monitoring and blood work assessment.
Common considerations include potential interactions with other medications and foods, particularly those affecting stomach acid or CYP3A4 enzyme activity. Regular monitoring through blood tests and imaging studies is essential to assess treatment response and manage any side effects that may occur during therapy.
Nicmel represents an important option in the targeted cancer therapy landscape, offering patients a mechanism-driven approach to managing serious hematologic and solid malignancies when prescribed and monitored by qualified oncologists.
Nicmel is a targeted tyrosine kinase inhibitor containing nilotinib as its active pharmaceutical ingredient, prescribed primarily for the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). This medication works by blocking specific proteins that promote abnormal cell growth, helping to slow or stop the progression of these blood and solid tumors.
Nilotinib has demonstrated clinical efficacy in managing both newly diagnosed and treatment-resistant CML cases, with established safety and tolerability profiles across multiple patient populations. Available in 150mg and 200mg capsule strengths, Nicmel allows for flexible dosing regimens tailored to individual patient needs and clinical response.
The medication is typically administered orally on an empty stomach, as food can significantly reduce its absorption. Standard dosing protocols vary based on disease stage and patient factors, with treatment duration determined by your healthcare provider based on response monitoring and blood work assessment.
Common considerations include potential interactions with other medications and foods, particularly those affecting stomach acid or CYP3A4 enzyme activity. Regular monitoring through blood tests and imaging studies is essential to assess treatment response and manage any side effects that may occur during therapy.
Nicmel represents an important option in the targeted cancer therapy landscape, offering patients a mechanism-driven approach to managing serious hematologic and solid malignancies when prescribed and monitored by qualified oncologists.